Gilead surges after WHO says remdesivir may combat coronavir...

Gilead’s share price has surged after health experts said its antiviral drug remdesivir is showing signs of efficacy against the deadly COVID-19 coronavirus outbreak.

Simple eye test could help screen kids for autism

Could Gilead's Sovaldi be the answer to COVID-19 coronavirus...

A Chinese research foundation has awarded $2.1m to four teams from Columbia University to identify antiviral drugs that work against the COVID-19 coronavirus – including a project investiga

Teva draws blank in phase 3 Tourette Syndrome trial

Teva’s late stage trials of a potential drug for Tourette Syndrome have drawn a blank, just when the troubled pharma needs to freshen up its portfolio.

Gilead poaches oncology expert Quigley from BMS

Gilead has poached an oncology research leader from Bristol-Myers Squibb, appointing Michael Quigley as senior vice president of research biology.

GW Pharma tops list of UK R&D spenders

Pharma is leading the way in R&D investment in the UK, with cannabis medicine specialist GW splurging almost 1,345% of its total revenue on research according to an analysis.